| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medicine/Division of cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States; Medicine/Division of Cardiology, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States
* To whom correspondence should be addressed. E-mail: molavibehzad{at}uams.edu.
Background
Current evidence points to renin-angiotensin system (RAS) as a key mediator in ischemia-reperfusion injury. Rosiglitazone, a peroxisome-proliferator activated receptor-gamma (PPAR-
ligand has recently been shown to confer cardioprotection against ischemia-reperfusion in animal models. We sought to examine the expression of angiotensin II receptors during PPAR-[[gamma]-mediated cardioprotection.
Materials and Methods
Male Sprague-Dawley rats (non-diabetic) were fed either regular rat chow (control diet group, n=9) or rosiglitazone-rich diet (rosiglitazone-rich diet group, n=9) and were subjected to one hour of myocardial ischemia followed by one hour of reperfusion. A third group of rats had only thoracotomy and pericardiotomy and served as a sham control group (n=9). Hemodynamics, infarct size and expression of Ang II type 1 and type 2 receptors (AT1 and AT2) were measured in all groups.
Results
There was a 58% reduction of infarct size in the rosiglitazone-rich diet group (P<0.01 vs. control diet group). Increased myocardial expression of AT1 receptors in the ischemic-reperfused myocardium was attenuated in the rosiglitazone-rich diet group (P<0.05 vs. control diet group). Importantly, myocardial AT2 mRNA and protein expression were significantly increased (by > 100 folds) in the rosiglitazone-rich diet group (P<0.05). These changes were accompanied by inhibition of P42/44 MAPK in the rosiglitazone-rich diet group, while the Akt1 expression, believed to mediate insulin sensitization, remained similar in all three groups.
Conclusion
The cardioprotective effects of rosiglitazone against myocardial ischemia-reperfusion injury are independent of its insulin-sensitizing properties and are associated with significant over-expression of AT2 receptors along with inhibition of P42/44 MAPK.
This article has been cited by other articles:
|
|
 |
|
  A. Jones, R. Deb, E. Torsney, F. Howe, M. Dunkley, Y. Gnaneswaran, D. Gaze, H. Nasr, I. M. Loftus, M. M. Thompson, et al. Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms Circulation, June 23, 2009; 119(24): 3125 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation Physiol Rev, January 1, 2009; 89(1): 147 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kuipers, P. van der Harst, G. Navis, L. van Genne, F. Morello, W. H. van Gilst, D. J. van Veldhuisen, and R. A. de Boer Nuclear Hormone Receptors as Regulators of the Renin-Angiotensin-Aldosterone System Hypertension, June 1, 2008; 51(6): 1442 - 1448. [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhang, F. He, R. Kuruba, X. Gao, A. Wilson, J. Li, T. R. Billiar, B. R. Pitt, W. Xie, and S. Li FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells Cardiovasc Res, February 1, 2008; 77(3): 560 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
